Product Overview
Composition
1 tab Memantine Hydrochloride 10 mg
Excipients:
microcrystalline cellulose,
calcium hydrogen phosphate,
croscarmellose sodium
silica colloidal
magnesium stearate.
The composition of the film shell :
Opadry II gray 45F27505 (hypromellose 2910 / 15cP, polydextrose, titanium dioxide, macrogol / macrogol-4000, iron dye black oxide)
pharmachologic effect
psychometabolic, nootropic.
Indications
- moderate to severe dementia in Alzheimer's disease.
Contraindications
hypersensitivity to any of the components of the drug; severe liver failure; pregnancy; breast-feeding; age up to 18 years (the effectiveness and safety of the drug have not been studied).
Precautions: epilepsy; renal failure; thyrotoxicosis; history of seizures; arterial hypertension; a history of myocardial infarction; heart failure.
Side effects
From the nervous system: dizziness, headache, drowsiness, impaired gait, confusion, hallucinations, convulsions, psychosis, increased irritability.
From the gastrointestinal tract: constipation, vomiting, pancreatitis, nausea. Infections and infestations: fungal infections.
From the CCC: increased blood pressure, venous thrombosis, thromboembolism.
From the body as a whole: general weakness, fatigue, allergic reactions.
Interaction
With simultaneous administration, it can weaken the effect of barbiturates and antipsychotics.
The effects of baclofen and dantrolene may change under the influence of memantine, so dose adjustment may be required. The effects of levodopa, dopamine receptor agonists and anticholinergics are enhanced with the simultaneous use of NMDA antagonists.
Due to the fact that memantine and amantadine are antagonists of NMDA receptors, simultaneous use should be avoided due to the risk of developing a toxic effect.
Combinations of memantine with ketamine, dextromethorphan, and phenytoin are also potentially toxic.
For the transport of amantadine, cimetidine, ranitidine, quinidine, quinine and nicotine, the same renal cationic system is used in the body, which can cause the interaction of these drugs with memantine, leading to an increase in its concentration in blood plasma.
How to take, course of administration and dosage
Inside, regardless of the meal.
During the first week, the daily dose is 5 mg (in the morning).
In the second week, the daily dose is 10 mg (5 mg 2 times a day). During the third week, the daily dose is 15 mg (10 mg in the morning and 5 mg in the evening).
From the fourth week, the daily dose is 20 mg. The maximum daily dose is 20 mg.
Special patient groups
Elderly patients.
Dose adjustment in elderly patients (over 65) is not required.
Impaired renal function.
In moderate renal failure (Cl creatinine 50–80 ml / min), dose adjustment is usually not required; with Cl creatinine 30–49 ml / min, the daily dose initially does not exceed 10 mg, then after 7 days, provided that the tolerance is good, the dose can be increased up to 20 mg.
In severe renal failure (Cl creatinine 5–29 ml / min), the daily dose should not exceed 10 mg.
Impaired liver function.
In mild to moderate hepatic insufficiency (Child-Pugh class A and B), dose adjustment is not required
Overdose
Symptoms: dizziness, tremor, agitation, drowsiness, dizziness, agitation, stupor, cramps, aggressiveness, hallucinations, gait instability, vomiting, diarrhea.
Treatment: gastric lavage, the appointment of activated carbon; symptomatic therapy. There is no specific antidote.
